Correspondence  by unknown
amine infusion before the decrease. By contrast, the observations of
Cladellas et al. concern patients who failed to achieve an adequate
heart rate response; it is not clear whether heart rate decrease
occurred in any patient. As we reported, only 1 of 14 patients with
paradoxical sinus deceleration was taking beta-blockers. We men-
tioned in our report that all our patients fasted for at least 3 h before
dobutamine stress echocardiography; mild hypovolemia may have
facilitated the occurrence of the vasodepressor response.
In our conclusions, we reported that paradoxical sinus deceleration
was most often seen in patients with coronary artery disease, but in
14% of our patients with heart rate decrease, there were no angio-
graphic, echocardiographic, electrocardiographic or clinical signs of
coronary artery disease. Sinus deceleration was often accompanied by
a decrease in blood pressure, nausea and chest pain. We believe that
sinus deceleration during dobutamine stress echocardiography is typ-
ically mediated by the Bezold-Jarisch reflex and is most commonly
seen in the presence of ischemia but may occur in its absence.
The echocardiographic signs of myocardial ischemia may be subtle
if heart rate is not increased and can be best appreciated by continuous
echocardiographic surveillance. Atropine is effective in increasing
heart rate in patients with paradoxical bradycardia and is recom-
mended in those with no manifestations of ischemia.
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F-18 FDG Uptake in Transplanted Heart
In their recent report, Rechavia et al. (1) concluded that a threefold
increase in the uptake of the glucose tracer analogue fluorine-18
2-deoxy-2-fluoroglucose (F-18 FDG) in transplanted hearts reflects a
preference for glucose as a substrate. The authors further concluded
that this preference for glucose may be due either to inefficient
utilization of glucose by the transplanted heart or to the influence of
circulating catecholamines.
This observation can be explained entirely by a change in the
relation between F-18 FDG and glucose. The latter is commonly
referred to as the “lumped constant” (LC) (2). This ratio between
tracer (F-18 FDG) and tracee (glucose) reflects the kinetic differences
between glucose and deoxyglucose transport and phosphorylation.
Most studies have used a fixed value of 0.67 to quantitate glucose
uptake from the F-18 FDG tracings (3–5), but we (6,7) and others (8)
have recently observed in the isolated working heart that the LC is
subject to significant variability, depending on the metabolic environ-
ment. Insulin and competing substrates to glucose cause a decrease in
the LC (6–8), whereas epinephrine and ischemia can cause an increase
in the LC (unpublished observations). An increase in the LC causes an
overestimation of glucose uptake, whereas a decrease in the LC results
in an underestimation of glucose uptake.
Thus, considering the results of Rechavia et al. (1) in light of the
experimental findings (6–8), the concept of an increased LC in the
transplanted hearts is in order. Such an increase would lead to the over-
estimation of glucose uptake. This effect may artificially introduce and
accentuate otherwise minor differences in glucose uptake. The possi-
bility of increased catecholamine sensitivity and the possible presence
of chronic “demand ischemia” in transplanted hearts would argue in
favor of this hypothesis.
A practical solution to this problem would be to determine the LC
individually for every study from the time-activity curves of F-18 FDG
accumulation (9). The results presented by Rechavia et al. (1) are
undoubtedly interesting, but we caution against drawing any conclu-
sions regarding the quantitation of glucose uptake or metabolism in
transplanted human heart.
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Reply
In their comment on the report by Rechavia et al. (1), Doenst and
Taegtmeyer make several important statements about the lumped
constant (LC) for fluorine-18 2-fluoro-2-deoxy-D-glucose (F-18 FDG)
and how changes in this variable would reflect on the quantitative
assessment of myocardial glucose utilization with this method. They
also surmize how the LC may differ between fasting conditions in
normal subjects and in transplant recipients.
We agree with the view that it is important to develop an
understanding of how the kinetics of F-18 FDG and glucose differ
under varying pathophysiologic conditions in humans, but the absence
of appropriate and unequivocal data means that predictions of how the
LC might change clinically are still clearly speculative.
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